ECONOMIC EFFECTS OF DIFFERENT ADMINISTRATION SCHEME OF PEMBROLIZUMAB IN ADVANCED OR ADJUVANT MELANOMA

被引：0
|
作者：
Rossi, D. [1 ]
Marcellusi, A. [2 ]
Mennini, F. S. [2 ]
机构：
[1] Univ Roma Tor Vergata, Fac Econ, Ctr Econ & Int Studies CEIS Econ Evaluat & HTA EE, Ceccano, FR, Italy
[2] Univ Roma Tor Vergata, Fac Econ, Ctr Econ & Int Studies CEIS Econ Evaluat & HTA EE, Rome, RM, Italy
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN145
引用
收藏
页码：S448 / S449
页数：2
相关论文
共 50 条
  • [1] Hyperprogression of advanced Melanoma Disease with Pembrolizumab adjuvant
    Geidel, G.
    Ammann, N.
    Schneider, S. W.
    Gebhardt, C.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 5 - 6
  • [2] Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
    Patel, Sapna P.
    Othus, Megan
    Chen, Yuanbin
    Wright, G. Paul
    Yost, Kathleen J.
    Hyngstrom, John R.
    Hu-Lieskovan, Siwen
    Lao, Christopher D.
    Fecher, Leslie A.
    Truong, Thach-Giao
    Eisenstein, Jennifer L.
    Chandra, Sunandana
    Sosman, Jeffrey A.
    Kendra, Kari L.
    Wu, Richard C.
    Devoe, Craig E.
    Deutsch, Gary B.
    Hegde, Aparna
    Khalil, Maya
    Mangla, Ankit
    Reese, Amy M.
    Ross, Merrick I.
    Poklepovic, Andrew S.
    Phan, Giao Q.
    Onitilo, Adedayo A.
    Yasar, Demet G.
    Powers, Benjamin C.
    Doolittle, Gary C.
    In, Gino K.
    Kokot, Niels
    Gibney, Geoffrey T.
    Atkins, Michael B.
    Shaheen, Montaser
    Warneke, James A.
    Ikeguchi, Alexandra
    Najera, Jose E.
    Chmielowski, Bartosz
    Crompton, Joseph G.
    Floyd, Justin D.
    Hsueh, Eddy
    Margolin, Kim A.
    Chow, Warren A.
    Grossmann, Kenneth F.
    Dietrich, Eliana
    Prieto, Victor G.
    Lowe, Michael C.
    Buchbinder, Elizabeth I.
    Kirkwood, John M.
    Korde, Larissa
    Moon, James
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (09): : 813 - 823
  • [3] Pembrolizumab for the treatment of advanced melanoma
    Burns, Michael C.
    O'donnell, Aidan
    Puzanov, Igor
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (08): : 867 - 873
  • [4] Pembrolizumab for patients with advanced melanoma
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2015, 16 (06): : E264 - E264
  • [5] Pembrolizumab: A Review in Advanced Melanoma
    Emma D. Deeks
    [J]. Drugs, 2016, 76 : 375 - 386
  • [6] Pembrolizumab: A Review in Advanced Melanoma
    Deeks, Emma D.
    [J]. DRUGS, 2016, 76 (03) : 375 - 386
  • [7] Adjuvant Pembrolizumab in Resected Stage III Melanoma
    Barker, Christopher A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (06): : 593 - 593
  • [8] Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety
    Nebhan, Caroline A.
    Johnson, Douglas B.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (06) : 583 - 590
  • [9] Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma
    Rutkowski, Piotr
    Czarnecka, Anna M.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (09) : 897 - 902
  • [10] NICE guidance on pembrolizumab for advanced melanoma
    Watson, Ian
    Dominguez, Pilar Pinilla
    Donegan, Eleanor
    Charles, Zoe
    Robertson, Janet
    Adam, E. Jane
    [J]. LANCET ONCOLOGY, 2016, 17 (01): : 21 - 22
12345